Sydney Jennings

FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, based on phase 3 data.

The FDA today issued a Complete Response Letter for Cingulate’s CTx-1301 for ADHD, citing CMC-related requests and no current safety or efficacy concerns.

Recent FDA updates include new actions in diabetes, hypertension, chronic HDV infection, bipolar depression, and CKD in type 1 diabetes.

Retatrutide phase 3 trials showed reductions in weight, A1C, osteoarthritis pain, and sleep apnea severity.

SLEEP 2026: Women with moderate-to-severe obstructive sleep apnea reported worse sleep, fatigue, anxiety, headaches, and nocturia than men.

Takeda reported phase 3 data showing zasocitinib achieved higher week 16 PASI 100 responses than deucravacitinib in plaque psoriasis.

The EEG-guided MeRT system is the first personalized, biomarker-guided neuromodulation technology to receive FDA clearance for PTSD.

High-risk rural patients were less likely than urban patients to be referred for obstructive sleep apnea evaluation in primary care.

SLEEP 2026: In an 8-week randomized trial, reishi mushroom extract reduced Insomnia Severity Index scores more than melatonin in adults with chronic insomnia.

SLEEP 2026: GLP-related home sleep testing made up 44% of primary care referrals, but many studies were negative or suboptimal, according to a late-breaking abstract.